A 5-month-old male with an isolated prolonged partial thromboplastin time

Laboratory Medicine

Volumn 38, Issue 4, 2007, Pages 218-221

  Gavino, Alde Carlo P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bypassing agents; Coagulation factor inhibitor; Hemophilia B; von Willebrand disease

Indexed keywords

EID: 58149523373     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/AHJKW4BXU8CPD7BA     Document Type: Article

References (12)

1. Miller JL, Rao AK. Blood Platelets and von Willebrand Disease. 747-69. In: McPherson RA and Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods, 21st ed. Philadelphia, PA: Saunders Elsevier; 2007.
2. Schmaier AH, Thornburg CD, Pipe SW. Coagulation and Fibrinolysis. 729-46. In: McPherson RA and Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods, 21st ed. Philadelphia, PA: Saunders Elsevier; 2007.
3. Astermark J. Overview of inhibitors. Semin Hematol. 2006;43:S3-S7.
4. Dunn AL, Abshire TC. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol. 2006;115:162-171.
5. Montgomery RR, Gill JC, Scott JP. Hemophilia and von Willebrand Disease, 1547-1576. In Nathan DG, Orkin SH, Ginsburg D, Look AT, eds. Nathan and Oski's Hematology of Infancy and Childhood, 6th ed. Philadelphia: WB Saunders. 2003.
6. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe hemophilia should be started at an early age but can be individualized. Br J Haematol. 1999;105:1109-1113.
7. Van Dijk K, Van Der Bom JG, Bax KN, et al. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica. 2004;89:189-194.
8. Leissinger CA. Inhibitor development in patients with hemophilia: An overview. Semin Hematol. 2006;43:S1-S2.
9. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia. 2006;12:52-60.
10. Peerlinck K, Arnout J, Gilles JG, et al. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost. 1997;77:80-86.
11. Mathew P. Current opinion on inhibitor treatment options. Semin Hematol. 2006;43:S8-S13.
12. Young G. New Approaches in the management of inhibitor patients. Acta Haematol. 2006:115:172-179.